Ian Hickson

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations

Life Sciences, Genetics, Molecular Biology +16

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Ian Hickson, Yan Zhao, Caroline J. Richardson et al. · Cancer Research · 2004 · 1.2K citations

Life Sciences, Molecular Biology, Oncology +16

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

Janine Arts, Peter King, Ann Marin et al. · Clinical Cancer Research · 2009 · 232 citations

Medicine, Oncology, Pharmacology +12

Discovery of 4-{4-[(3<i>R</i>)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1<i>H</i>-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

Kevin M. Foote, Kevin Blades, Anna Cronin et al. · Journal of Medicinal Chemistry · 2013 · 215 citations · Full text

Medicine, Oncology, Pharmacology +13